RT Book, Section
A1 Marciano, Sebastián
A1 Gaite, Luis Alejandro
A1 Mullen, Eduardo Gustavo
A2 Molmenti, Ernesto Pompeo
A2 Santibañes, Martin de
A2 Santibañes, Eduardo de
SR Print(0)
ID 1180107596
T1 Liver Transplantation in Nonalcoholic Fatty Liver Disease
T2 Liver Transplantation: Operative Techniques and Medical Management
YR 2021
FD 2021
PB McGraw Hill
PP New York, NY
SN 9781260462517
LK accesssurgery.mhmedical.com/content.aspx?aid=1180107596
RD 2024/04/20
AB Due  to  the  increasing  incidence  of  obesity  in  recent  years,  nonalcoholic  fatty  liver  disease  (NAFLD)  has  become  the  most  common  chronic  liver  disease  in  the  Western  world.1The  spectrum  of  NAFLD  goes  through  different  stages,  from  simple  steatosis  and  nonalcoholic  steatohepatitis  (NASH)  to  cirrhosis  and  end-stage  liver  disease.  Figure  20-1  to  20-5Recent  data  show  a  prevalence  as  high  as  46%  for  NAFLD,  12%  for  NASH,  and  2.7%  for  advanced  fibrosis  in  the  general  U.S.  population.2The  United  Network  for  Organ  Sharing/Organ  Procurement  and  Transplantation  Network  (UNOS/OPTN)  data  demonstrate  that  NASH  has  become  the  second  leading  cause  of  chronic  liver  disease  among  new  patients  on  waiting  list  for  liver  transplantation  in  2013,  showing  an  increase  of  170%.3Data  from  the  UNOS/OPTN  registry  showed  that  NASH  etiology  rose  4-fold  from  2002  to  2012  in  patients  with  hepatocellular  carcinoma  who  underwent  liver  transplantation.4NASH  is  becoming  the  leading  cause  of  LT  in  many  regions.  This  is  explained  by  the  increasing  number  of  patients  with  NASH-related  liver  disease  and  the  emergence  of  highly  effective  antiviral  therapies  for  HCV.